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Objective: Endothelin-1 concentrations are increased in patients with increased
mean pulmonary arterial pressure, pulmonary blood flow, and pulmonary vascular
resistance. However, endothelin-1 concentrations have not been well characterized
in patients with congenital heart disease and normal pulmonary vascular resistance.
In particular, it is unclear whether pressure or flow is the key regulator of endothe-
lin- 1 in this setting. We tested the hypothesis that pulmonary blood pressure and not
flow is associated with net endothelin-1 production in patients with congenital heart
disease and normal pulmonary vascular resistance.
Methods: With a commercially available immunoassay, we measured endothelin-1
concentrations in pulmonary arterial and pulmonary venous plasma of 56 consec-
utive patients with congenital heart disease and pulmonary vascular resistance less
than 2 U · m2 undergoing cardiac catheterization. We used multiple linear regression
to analyze the effect of demographic and hemodynamic variables on pulmonary
arterial and venous endothelin-1 concentrations and on the change of endothelin-1
concentration over the pulmonary vascular bed.
Results: Multiple linear regression revealed that of all the hemodynamic variables
tested, mean pulmonary arterial pressure had the greatest effect on increasing the
change of endothelin-1 concentration over the pulmonary vascular bed (P .0001).
Pulmonary blood flow did not have any effect on endothelin-1 concentrations or on
the change of endothelin-1 concentration over the pulmonary vascular bed.
Conclusions: This study shows that pulmonary blood pressure and not flow is
associated with net endothelin-1 production in patients with congenital heart disease
and normal pulmonary vascular resistance.
Pulmonary hypertension and increased pulmonary vascular resistance(PVR) may develop in patients with congenital heart disease (CHD)and increased pulmonary blood pressure and flow.1 Ultimately, pul-monary hypertension and increased PVR lead to advanced pulmonaryvascular disease. Although the morphologic features of pulmonaryhypertension have been well described,2-4 the mechanisms leading to
advanced pulmonary vascular disease are still poorly understood.5-8
Increasing evidence emphasizes the role of endothelin-1 (ET-1) in patients with
various forms of pulmonary hypertension, increased PVR, and advanced pulmonary
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vascular disease.6,9 In these patients there is a net produc-
tion of ET-1 by the pulmonary vascular bed, caused either
by decreased clearance, true increased production, or a
combination of two.6,9 In light of these findings, the first
ET-1 receptor antagonist (bosentan) has recently been ap-
proved for treatment of patients with pulmonary hyperten-
sion.10
However, little is known about the alterations of ET-1
concentrations in patients with CHD and normal PVR. In
particular, it is uncertain whether pressure or flow is the
major trigger for net ET-1 production in these patients.11-16
The reason for this uncertainty is that research has focused
on the effects of flow, not pressure.11,17,18
Recently, a study in bovine pulmonary cell cultures
indicated that pressure and not flow is the major trigger for
ET-1 production by the pulmonary endothelium.19 We
therefore tested the hypothesis that pulmonary blood pres-
sure and not flow is associated with net ET-1 production in
patients with CHD and normal PVR.
For this study we assessed the effects of pressure, flow,
and several other hemodynamic and demographic variables
on pulmonary arterial and venous ET-1 concentrations and
on the change of ET-1 concentration over the pulmonary
vascular bed in patients with CHD and normal PVR. We
used the change of ET-1 concentration over the pulmonary
vascular bed as an indicator of net ET-1 clearance or pro-
duction by the pulmonary vascular bed.
Methods
Patient Population
During the 10-month study period, 65 consecutive patients in our
hospital (Deutsches Herzzentrum Mu¨nchen, Munich, Germany)
who fulfilled the following criteria were enrolled in the study:
routine diagnostic cardiac catheterization, routine catheter access
to pulmonary veins, PVR less than 2 U · m2, and CHD without
cavopulmonary connections. Patients with cavopulmonary con-
nections were excluded because accurate determination of pulmo-
nary blood flow is difficult in these patients. Because of a coeffi-
cient of variation of at least 0.15 between the dual measurements
of ET-1 concentration, 9 original patients were later excluded.
Thus the final study population consisted of 56 patients (29 of
them female). The mean age of the patients was 10.8 15.7 years.
The underlying diagnoses were secundum type atrial septal defect
(n  23), sinus venosus defect (n  1), ventricular septal defect (n
 3), atrioventricular septal defect (n  2), congenitally corrected
transposition of the great arteries with ventricular septal defect (n
 2), double-outlet right ventricle (n  3), Ebstein anomaly (n 
1), persistent foramen ovale (n  2), tetralogy of Fallot (n  4),
transposition of the great arteries with Mustard procedure (n  2),
uncorrected transposition of the great arteries (n  1), pulmonary
valve stenosis (n  1), pulmonary sling (n  1), distal pulmonary
stenosis (n  1), dilatation of the ascending aorta (n  1),
coarctation of the aorta (n  1), and others (n  7). None of the
patients had large aortopulmonary collaterals. The study was ap-
proved by the institutional review board, and informed consent
was obtained from the patient or from the parents.
Study Design
ET-1 concentrations were measured in the pulmonary artery and
corresponding vein of all patients enrolled in the study. The effect
of hemodynamic and demographic variables on pulmonary arterial
and venous ET-1 concentrations and on the change of ET-1 over
the pulmonary vascular bed were assessed by multiple linear
regression analysis.
Measurement of Hemodynamic Variables
Hemodynamic variables were measured during cardiac catheter-
ization with patients under general anesthesia or sedation. Oxygen
consumption was measured directly with a flow-through system20
in 57% of the patients. If this was not possible, oxygen consump-
tion was estimated from age, sex, and heart rate by the method of
LaFarge and Miettinen.21 Mean pulmonary arterial pressure
(mPAP), mean pulmonary venous pressure, and mean ascending
aortic pressure were measured with fluid-filled catheters connected
to pressure transducers. Pulmonary and systemic blood flows were
calculated by the standard Fick method and indexed for body
surface area (BSA). The ratio of pulmonary to systemic blood
flow, PVR, and systemic vascular resistance were calculated ac-
cording to standard formulas and indexed for BSA.
Blood Sampling
During cardiac catheterization before angiography, 1.3-mL blood
samples were taken from the left or right pulmonary artery and a
corresponding pulmonary vein. The samples were collected in
prechilled commercially available blood sample tubes containing
ethylenediaminetetraacetic acid. After centrifugation at 4°C, the
plasma samples were stored at 70°C until the ET-1 assay. The
time lapse between blood sampling and freezing of the plasma
samples was recorded.
ET-1 Assay
Plasma ET-1 concentrations were measured with a commercially
available immunoassay kit (R&D Systems, Minneapolis, Minn).
Cross-reactivities with ET-2, ET-3, and big ET-1 were 27%, 8%,
and less than 1%, respectively. This assay used a quantitative
sandwich enzyme immunoassay technique. A monoclonal anti-
body specific for ET-1 was precoated onto a microplate. Standards
and samples were pipetted into the wells, and the immobilized
antibody bound any ET-1 present. After any unbound substance
was washed away, an enzyme-linked monoclonal antibody specific
for ET-1 was added to the wells. Any unbound antibody-enzyme
reagent was then washed away. An enhanced luminol-peroxide
substrate solution was then added to the wells, and light was
produced in proportion to the amount of ET-1 bound in the initial
step. A microplate luminometer was used to measure the intensity
of the light emitted. All samples were pipetted into two wells; thus
each sample was measured twice. The arithmetic mean of the two
measurements was used for the statistical analysis. A coefficient of
variation of at least 0.15 between the two measurements led to a
second dual measurement or exclusion of the patient if not enough
plasma was available.
Statistical Analysis
Three multiple linear regressions with a backward selection algo-
rithm analyzed the effects of several independent variables on
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three dependent variables. The dependent variables were the ET-1
concentrations in the pulmonary artery and vein and the change in
ET-1 concentration over the pulmonary vascular bed. The change
in ET-1 concentration was defined as the ET-1 concentration in the
pulmonary vein minus the ET-1 concentration in the pulmonary
artery divided by the ET-1 concentration in the pulmonary artery.
A positive change therefore indicates an increase of ET-1 concen-
tration over the pulmonary vascular bed; a negative change indi-
cates a decrease. The independent variables of the multiple regres-
sion analysis were age, sex, BSA, hemoglobin concentration, time
between blood sampling and freezing, diagnosis group, and several
hemodynamic variables: mPAP, mean pulmonary venous pressure,
mean ascending aortic pressure, pulmonary blood flow, ratio of
systemic to pulmonary flow, PVR, and systemic vascular resis-
tance. Results are presented as mean  SD. SPSS for Windows
version 11.0 (SPSS Inc, Chicago, Ill) was used for statistical
analysis.
Results
Our main finding from multiple linear regression analysis
was that of all the hemodynamic variables tested, mPAP had
the greatest effect on ET-1 concentrations in patients with
CHD and normal PVR (Table 1). Specifically, increased
mPAP increased the change of ET-1 concentration over the
pulmonary vascular bed (Figure 1). The linear regression in
Figure 1 seemed to be predominantly driven by the patient
in the upper right corner. After exclusion of this patient,
however, the linear regression did not change considerably.
More importantly, when we repeated the multiple linear
regression analysis without this patient (data not shown),
the highly significant results remained as depicted in Table
1.
The other two variables that had a significant effect on
ET-1 concentrations were BSA and PVR (Table 1). To
ensure that these three variables were not dependent on each
other, we carried out a correlation analysis for these three
variables. None of the variable pairs had a coefficient of
correlation greater than 0.5 (data not shown), thus ensuring
the independence of these three variables. None of the other
variables studied (pulmonary blood flow, ratio of pulmo-
nary to systemic flow, mean pulmonary venous pressure,
mean ascending aortic pressure, systemic vascular resis-
tance, sex, age, diagnosis, hemoglobin level, and time be-
tween blood sampling and freezing) had any significant
effect on ET-1 concentrations.
For the patient group as a whole, the following hemo-
dynamic variables were determined: mPAP 12.3  6.6 mm
Hg, mean pulmonary venous pressure 5.9  2.2 mm Hg,
mean ascending aortic pressure 61.4  11.1 mm Hg, pul-
monary blood flow 7.0  4.9 L/(min · m2), ratio of pulmo-
nary to systemic flow 1.9 1.1, PVR 1.0 0.5 U · m2, and
systemic vascular resistance 17.2 9.1 U · m2. Hemoglobin
concentration was 12.0  2.0 g/dL. The mean ET-1 con-
centration dropped from 1.3  0.7 pg/mL in the pulmonary
artery to 1.2  0.8 pg/mL in the pulmonary vein. However,
the change of ET-1 concentration over the pulmonary vas-
cular bed ranged from a 40.7% decrease to a 71.0% increase
(mean 9.5%  21.8% decrease; Figure 1).
Discussion
This study demonstrates that pulmonary blood pressure and
not flow is associated with net ET-1 production in the lungs
of patients with CHD and normal PVR. Multiple linear
regression analysis showed that of all the variables studied,
mPAP had the greatest effect on ET-1 concentrations in
patients with CHD and normal PVR (Table 1). Specifically,
as mPAP increased, the change of ET-1 concentration over
the pulmonary vascular bed increased (Figure 1). Similar
results were found recently by studying bovine pulmonary
cell cultures.19 Moreover, neither pulmonary blood flow nor
the ratio of pulmonary to systemic flow had a significant
effect on ET-1 concentrations. Greater BSA was associated
with decreased ET-1 concentrations. Because BSA in-
creases with age, this finding is consistent with previous
observations that increasing age from infancy to adoles-
cence is correlated with decreasing ET-1 concentrations.22
A review of studies of the effects of pulmonary arterial
pressure and flow on ET-1 concentrations in patients with
CHD reveals conflicting results.11-16 The explanation may
be that all studies focused on the effects of flow, thus
neglecting the effects of pressure. Further, none of the
studies used multiple regression analysis, thus ignoring the
TABLE 1. Hemodynamic and demographic variables that significantly affected ET-1 concentrations after multiple linear
regression analysis (n  56)
ET-1 concentration (standardized effect,* regression coefficient [95% CI])
In PA In PV Change over pulm vasc bed†
Mean pulmonary artery pressure 3.89†, 0.04 (0.02 to 0.07) 5.78†, 1.96 (1.28 to 2.64)
Body surface area 4.28†,0.58 (0.85 to0.31) 4.24†,0.62 (0.91 to0.33) 2.22†,8.79 (16.72 to0.85)
Pulmonary vascular resistance 2.98‡, 0.49 (0.16 to 0.82)
*Regression coefficient/standard error of regression coefficient. PA, Pulmonary artery; PV, pulmonary vein; Change over pulm vasc bed, ET-1 concentration
in the pulmonary vein minus the ET-1 concentration in the pulmonary artery divided by the ET-1 concentration in the pulmonary artery.
†P  .0001.
‡P  .0044.
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interdependence of pressure and flow. Our results clarify the
reason for these conflicting results by showing with multiple
regression analysis of a large number of patients that pres-
sure, not flow, is the major trigger for ET-1 production in
patients with CHD and normal PVR.
A detailed look at our results for patients with CHD and
normal PVR suggests that the pulmonary vascular bed
seems to be a net ET-1 clearance site when mPAP is low
(decrease of ET-1 over the pulmonary vascular bed, change
is negative; Figure 1). Further, it seems to shift to a net ET-1
production site when mPAP is high (increase of ET-1 over
the pulmonary vascular bed, change is positive; Figure 1).
The possibility of this shift is supported by similar findings
in healthy rats with normal mPAP23 and in patients with
elevated mPAP and PVR.6,8 In healthy rats with normal
mPAP, the pulmonary vascular bed was found to be a net
ET-1 clearance site.23 In contrast, in patients with elevated
mPAP and PVR, the pulmonary vascular bed was found to
be a net ET-1 production site.6,8 The net ET-1 production in
these patients was due to decreased clearance of ET-1.6,8
Studies investigating the pulmonary clearance of ET-1 in
patients with shunt-related CHD are needed to confirm these
implications.
Furthermore, one can speculate that the results of this
study may explain the clinical experience that increased
pulmonary blood flow does not in itself lead to increased
PVR. Clinical experience shows that even longstanding
increased pulmonary blood flow, as in patients with atrial
septal defects, mostly does not lead to increased PVR. On
the other hand, increased pulmonary blood flow accompa-
nied by increased pulmonary blood pressure, as in patients
with large ventricular septal defects or a large patent ductus
arteriosus, leads to drastically increased PVR. Additionally,
the important role of ET-1 in patients with increased PVR
has been shown.6,9 These observations, in combination with
our finding that pressure and not flow is the major trigger for
net ET-1 production in patients with CHD and normal PVR,
may explain why patients with increased flow alone do not
have increased PVR, whereas patients with combined in-
creased flow and pressure do.
Limitations
A limitation of our study is that the observed ET-1 concen-
trations were very low. Thus the detected differences could
have been due to systematic measurement problems. How-
ever, we carefully ensured that the measured concentrations
Figure 1. Linear regression of mPAP (variable with greatest effect as assessed by multiple linear regression) and
change of ET-1 concentration over pulmonary vascular bed of 56 patients with CHD and normal PVR. Positive
change indicates increase of ET-1 concentration over pulmonary vascular bed; negative change indicates
decrease. Change of ET-1 concentration was defined as ET-1 concentration in pulmonary vein minus ET-1
concentration in pulmonary artery divided by ET-1 concentration in pulmonary artery. Linear regression results (y
 2.1, x 35.5, r2 0.409, P < .0001) seemed to be predominantly driven by patient in upper right corner. However,
linear regression did not change considerably after exclusion of this patient. More importantly, when we repeated
multiple linear regression analysis without this patient, highly significant results remained, as depicted in Table
1. Note that pulmonary vascular bed seems to be net ET-1 clearance site when mPAP is low (change is negative)
and seems to shift to net ET-1 production site when mPAP is high (change is positive).
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reflected the genuine situation by carrying out dual mea-
surements. A coefficient of variation of at least 0.15 be-
tween the two measurements led to a second dual measure-
ment or to exclusion of the patient if not enough plasma was
available. Furthermore, we carefully analyzed the data by
multiple regression analysis. We think that multiple linear
regression is the appropriate way to detect interdependence
of hemodynamic variables with concentrations of circulat-
ing substances, because no single hemodynamic variable is
independent of the others (some are even calculated from
others). Additionally, the immunoassay kit that we used in
this study is quite accurate in detecting low concentrations
and small concentration differences without extraction. For
this kit, cross-reactivity with the ET-1 precursor big ET-1 is
 1%. In contrast, nearly all studies investigating the rela-
tionship of ET-1 and hemodynamic variables in patients
with CHD and increased pulmonary blood flow or pressures
have used ET-1 assays with large cross-reactivities (up to
80%) with big ET-1.6,11,12,14,15,22 These large cross-reactiv-
ities make the interpretation of the results problematic. The
reason is that active ET-1 is produced by ET-1 converting
enzyme from the precursor big ET-1. It is known that ET-1
converting enzyme is strongly up-regulated in lambs with in
utero placement of an aortopulmonary shunt,24 so measuring
ET-1 with an assay that has a strong cross-reactivity with big
ET-1 in this setting must lead to confusing data.
Another limitation of our study is that ET-1 is not a
single-acting mediator but is regulated in a fine-tuned man-
ner.24 Therefore future studies should investigate the entire
ET-1 cascade in patients with shunt-related CHD.
A final limitation of this study is the variety of types of
CHD in the study population. However, we believe that this
problem was appropriately addressed by carrying out a
multiple regression analysis, and we showed that the type of
CHD was not related to ET-1 concentrations. Notably, after
multiple linear regression, ET-1 concentrations in the larg-
est group (patients with secundum type atrial septal defect)
did not act differently than the ET-1 concentrations of the
other groups. This finding suggests that the underlying
hemodynamic condition does not contribute to the changes
in ET-1 concentrations in pulmonary arterial and venous
blood. This finding is supported by a previous study, which
also did not find any significant differences in ET-1 con-
centrations in patients with different types of CHD.14 If the
study population had been more uniform, and therefore
smaller, any influence of various hemodynamic conditions
would have been avoided; however, the smaller number of
blood samples would have very likely made a statistical
analysis impossible.
Conclusion
In this study we investigated the effects of hemodynamic
and demographic variables on ET-1 concentrations in a
large number of patients with CHD by carrying out dual
measurements of ET-1 concentration and applying multiple
regression analysis. We found that pulmonary blood pres-
sure and not flow is associated with net ET-1 production in
patients with CHD and normal PVR, because of all of the
hemodynamic variables studied, mPAP had the strongest
effect on ET-1 concentrations. Studying agents that manip-
ulate the ET-1 cascade should reveal whether a therapeutic
approach that influences the PVR in this setting can be
developed. ET receptor antagonists promise to play an im-
portant role.
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